Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
S Liewer, A Huddleston - Expert opinion on investigational drugs, 2018 - Taylor & Francis
Introduction: Aurora kinases are essential mediators in cell mitosis. Amplification of these
kinases can lead to the development of malignancy and may be associated with inferior …
kinases can lead to the development of malignancy and may be associated with inferior …
An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor
CT Durlacher, ZL Li, XW Chen, ZX He… - Clinical and …, 2016 - Wiley Online Library
Summary Human Aurora kinases, including Aurora kinase A (AURKA), B (AURKB), and C
(AURKC), play an essential role in mitotic events such as monitoring of the mitotic …
(AURKC), play an essential role in mitotic events such as monitoring of the mitotic …
[HTML][HTML] Talazoparib does not interact with ABCB1 transporter or cytochrome P450s, but modulates multidrug resistance mediated by ABCC1 and ABCG2: an in vitro …
Z Sabet, D Vagiannis, Y Budagaga, Y Zhang… - International Journal of …, 2022 - mdpi.com
Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP)
inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has …
inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has …
Murine central nervous system and bone marrow distribution of the aurora a kinase inhibitor alisertib: Pharmacokinetics and exposure at the sites of efficacy and …
Important challenges in develo** drugs that target central nervous system (CNS) tumors
include overcoming barriers for CNS delivery and reducing systemic side effects. Alisertib …
include overcoming barriers for CNS delivery and reducing systemic side effects. Alisertib …
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity …
D Vagiannis, Y Zhang, Y Budagaga, E Novotna… - Toxicology and Applied …, 2022 - Elsevier
Abstract Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically
tested in late-phase trials for the therapy of various malignancies. In the present work, we …
tested in late-phase trials for the therapy of various malignancies. In the present work, we …
[HTML][HTML] Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging
V Bernard-Gauthier, JJ Bailey, S Berke… - Molecules, 2015 - mdpi.com
Over the last 20 years, intensive investigation and multiple clinical successes targeting
protein kinases, mostly for cancer treatment, have identified small molecule kinase inhibitors …
protein kinases, mostly for cancer treatment, have identified small molecule kinase inhibitors …
Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO2: Opportunities for 11C Radiochemistry
M Ahamed, J Verbeek, U Funke, J Lecina… - …, 2016 - Wiley Online Library
Carbon dioxide (CO2) as a synthon in organic transformations is very useful, especially
when combined with transition metal catalysts. CO2 insertion on carbon (Aryl)‐metal is are …
when combined with transition metal catalysts. CO2 insertion on carbon (Aryl)‐metal is are …
Inhibition of Aurora A kinase by alisertib induces autophagy and cell cycle arrest and increases chemosensitivity in human hepatocellular carcinoma HepG2 cells
Q Zhu, X Yu, ZW Zhou, C Zhou… - Current cancer drug …, 2017 - benthamdirect.com
Background: Aurora A kinase represent a feasible target in cancer therapy. Objective: To
evaluate the proteomic response of human liver carcinoma cells to alisertib (ALS) and …
evaluate the proteomic response of human liver carcinoma cells to alisertib (ALS) and …
[HTML][HTML] Comparison of in vitro assays in selecting radiotracers for in vivo P-glycoprotein PET imaging
RM Raaphorst, H Savolainen, M Cantore… - Pharmaceuticals, 2017 - mdpi.com
Positron emission tomography (PET) imaging of P-glycoprotein (P-gp) in the blood-brain
barrier can be important in neurological diseases where P-gp is affected, such as Alzheimer´ …
barrier can be important in neurological diseases where P-gp is affected, such as Alzheimer´ …
A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells
Q Zhu, M Luo, C Zhou, Z Zhou, Z He… - American Journal of …, 2017 - pmc.ncbi.nlm.nih.gov
Targeted therapy may provide survival benefit for advanced hepatocellular carcinoma
(HCC) and Aurora A kinase (AURKA) represents a feasible target in cancer treatment. The …
(HCC) and Aurora A kinase (AURKA) represents a feasible target in cancer treatment. The …